{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:59:48Z","timestamp":1791082788392,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with a poor prognosis and limited response to current therapies. Cancer stem cells (CSCs) contribute to this heterogeneity, driving tumor progression, immune evasion, and therapeutic resistance. Epigenetic regulators have emerged as pivotal modulators of CSC phenotypes. The histone methyltransferase SETDB1, a key stemness factor in both embryonic and adult stem cells, catalyzes H3K9 trimethylation (H3K9me3) and acts as a major oncogenic driver in a wide range of solid and hematological malignancies. Yet, its specific role in maintaining stemness and contributing to therapeutic resistance in HCC remains poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Integrative analyses of bulk and single-cell transcriptomic datasets from public HCC cohorts were performed. Tumors were stratified by SETDB1 expression, followed by pathway enrichment, immune deconvolution, and stemness scoring. Associations with clinical outcomes, immune phenotypes, drug resistance signatures, and chromatin-binding partners (DNMT3A, TRIM28, HDAC1) were also explored. The role of SETDB1 was then examined in vitro, where a stem-like phenotype was induced in HCC cell lines under hypoxic conditions, and patterns of SETDB1 expression and stemness marker levels were assessed following paclitaxel treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SETDB1-low tumors were enriched in well-differentiated, immunologically active subclasses and were associated with increased predicted responsiveness to immune checkpoint blockade (ICB), sorafenib, and transarterial chemoembolization. Conversely, SETDB1-high tumors exhibited transcriptional features of dedifferentiation, elevated stemness scores, and enrichment in aggressive molecular subtypes. These tumors also displayed higher TP53 mutation rates, reduced immune infiltration, immune exclusion signatures, and activation of pathways linked to ferroptosis and ABC transporter dysfunction, consistent with resistance to ICB and conventional therapies. SETDB1 expression was also associated with hypoxia-related pathways, suggesting a role in maintaining CSC niches. In vitro, hypoxia-induced stemness coincided with increased SETDB1 levels, whereas paclitaxel treatment decreased both SETDB1 expression and stemness markers. A chromatin risk score incorporating SETDB1 and its partners predicted poor disease-free survival independently of clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SETDB1 defines a stemness-enriched, immune-resistant HCC subtype associated with poor outcomes and therapeutic failure. Correlations between SETDB1 expression and stem-like features in vitro suggest a potential role in maintaining CSC phenotypes, supporting its relevance as a biomarker and candidate for epigenetic- and CSC-directed therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13402-025-01157-3","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:26:10Z","timestamp":1767709570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The epigenetic regulator SETDB1 as a key component of cancer stem cells and drug resistance in primary liver cancer"],"prefix":"10.1007","volume":"49","author":[{"given":"Ma\u00ebl","family":"Padelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Desterke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Devocelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Uzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Giron-Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1157_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"H. Rumgay, M. Arnold, J. Ferlay, O. Lesi, C.J. Cabasag, J. Vignat et al., Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77, 1598\u20131606 (2022). https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021","journal-title":"J. Hepatol."},{"key":"1157_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"A.G. Singal, E. Zhang, M. Narasimman, N.E. Rich, A.K. Waljee, Y. Hoshida et al., HCC surveillance improves early Detection, curative treatment Receipt, and survival in patients with cirrhosis: A systematic review and Meta-Analysis. J. Hepatol. 77, 128\u2013139 (2022). https:\/\/doi.org\/10.1016\/j.jhep.2022.01.023","journal-title":"J. Hepatol."},{"key":"1157_CR3","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.bbadis.2018.01.027","volume":"1864","author":"Z-H Liu","year":"2018","unstructured":"Z.-H. Liu, B.-F. Lian, Q.-Z. Dong, H. Sun, J.-W. Wei, Y.-Y. Sheng et al., Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2360\u20132368 (2018). https:\/\/doi.org\/10.1016\/j.bbadis.2018.01.027","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"1157_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pharmthera.2013.01.014","volume":"138","author":"Y Shiozawa","year":"2013","unstructured":"Y. Shiozawa, B. Nie, K.J. Pienta, T.M. Morgan, R.S. Taichman, Cancer stem cells and their role in metastasis. Pharmacol. Ther. 138, 285\u2013293 (2013). https:\/\/doi.org\/10.1016\/j.pharmthera.2013.01.014","journal-title":"Pharmacol. Ther."},{"key":"1157_CR5","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"L.T.H. Phi, I.N. Sari, Y.-G. Yang, S.-H. Lee, N. Jun, K.S. Kim et al., Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 5416923 (2018). https:\/\/doi.org\/10.1155\/2018\/5416923","journal-title":"Stem Cells Int."},{"key":"1157_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"A. Kreso, J.E. Dick, Evolution of the cancer stem cell model. Cell. Stem Cell. 14, 275\u2013291 (2014). https:\/\/doi.org\/10.1016\/j.stem.2014.02.006","journal-title":"Cell. Stem Cell."},{"key":"1157_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcmgh.2020.09.003","volume":"11","author":"J Liu","year":"2020","unstructured":"J. Liu, P. Li, L. Wang, M. Li, Z. Ge, L. Noordam et al., Cancer-Associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance. Cell. Mol. Gastroenterol. Hepatol. 11, 407\u2013431 (2020). https:\/\/doi.org\/10.1016\/j.jcmgh.2020.09.003","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1157_CR8","doi-asserted-by":"publisher","first-page":"175883591881628","DOI":"10.1177\/1758835918816287","volume":"10","author":"N Wang","year":"2018","unstructured":"N. Wang, S. Wang, M.-Y. Li, B.-G. Hu, L.-P. Liu, S.-L. Yang et al., Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies. Ther. Adv. Med. Oncol. 10, 1758835918816287 (2018). https:\/\/doi.org\/10.1177\/1758835918816287","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1157_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-020-00252-1","volume":"5","author":"Y Chen","year":"2020","unstructured":"Y. Chen, B. Ren, J. Yang, H. Wang, G. Yang, R. Xu et al., The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal. Transduct. Target. Ther. 5, 143 (2020). https:\/\/doi.org\/10.1038\/s41392-020-00252-1","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1157_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.2217\/epi-2018-0173","volume":"11","author":"AA Emran","year":"2019","unstructured":"A.A. Emran, D.M. Marzese, D.R. Menon, H. Hammerlindl, F. Ahmed, E. Richtig et al., Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Epigenomics. 11, 732\u2013737 (2019). https:\/\/doi.org\/10.2217\/epi-2018-0173","journal-title":"Epigenomics"},{"key":"1157_CR11","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1128\/MCB.24.6.2478-2486.2004","volume":"24","author":"JE Dodge","year":"2004","unstructured":"J.E. Dodge, Y.-K. Kang, H. Beppu, H. Lei, E. Li, Histone H3-K9 methyltransferase ESET is essential for early development. Mol. Cell. Biol. 24, 2478\u20132486 (2004). https:\/\/doi.org\/10.1128\/MCB.24.6.2478-2486.2004","journal-title":"Mol. Cell. Biol."},{"key":"1157_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2016-01-694810","volume":"128","author":"S Koide","year":"2016","unstructured":"S. Koide, M. Oshima, K. Takubo, S. Yamazaki, E. Nitta, A. Saraya et al., Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes. Blood. 128, 638\u2013649 (2016). https:\/\/doi.org\/10.1182\/blood-2016-01-694810","journal-title":"Blood"},{"key":"1157_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/cancers11081143","volume":"11","author":"J Batham","year":"2019","unstructured":"J. Batham, P.S. Lim, S. Rao, SETDB-1: A potential epigenetic regulator in breast cancer metastasis. Cancers (Basel). 11, 1143 (2019). https:\/\/doi.org\/10.3390\/cancers11081143","journal-title":"Cancers (Basel)"},{"key":"1157_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70116","author":"Y-H Chang","year":"2025","unstructured":"Y.-H. Chang, S. Goyama, The role of histone methyltransferase SETDB1 in normal and malignant hematopoiesis. Cancer Sci. (2025). https:\/\/doi.org\/10.1111\/cas.70116","journal-title":"Cancer Sci."},{"key":"1157_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.18632\/oncotarget.28688","volume":"16","author":"E Verdier","year":"2025","unstructured":"E. Verdier, N. Gaspar, M.E. Marques Da Costa, A. Marchais, SETDB1 amplification in osteosarcomas: insights from its role in healthy tissues and other cancer types. Oncotarget. 16, 51\u201362 (2025). https:\/\/doi.org\/10.18632\/oncotarget.28688","journal-title":"Oncotarget"},{"key":"1157_CR16","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.3390\/cells13242102","volume":"13","author":"C-Q Yin","year":"2024","unstructured":"C.-Q. Yin, C.-Q. Song, Tumor intrinsic immunogenicity suppressor SETDB1 worsens the prognosis of patients with hepatocellular carcinoma. Cells. 13, 2102 (2024). https:\/\/doi.org\/10.3390\/cells13242102","journal-title":"Cells"},{"key":"1157_CR17","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1080\/21655979.2021.2023792","volume":"13","author":"J Zhou","year":"2022","unstructured":"J. Zhou, J. Che, L. Xu, W. Yang, Y. Li, W. Zhou et al., Enhancer of Zeste homolog 2 promotes hepatocellular cancer progression and chemoresistance by enhancing protein kinase B activation through microRNA-381-mediated SET domain bifurcated 1. Bioengineered. 13, 5737\u20135755 (2022). https:\/\/doi.org\/10.1080\/21655979.2021.2023792","journal-title":"Bioengineered"},{"key":"1157_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"J. Liu, T. Lichtenberg, K.A. Hoadley, L.M. Poisson, A.J. Lazar, A.D. Cherniack et al., An integrated TCGA Pan-Cancer clinical data resource to drive High-Quality survival outcome analytics. Cell. 173, 400\u2013416e11 (2018). https:\/\/doi.org\/10.1016\/j.cell.2018.02.052","journal-title":"Cell"},{"key":"1157_CR19","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013). https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci. Signal."},{"key":"1157_CR20","doi-asserted-by":"publisher","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","volume":"46","author":"SV Vasaikar","year":"2018","unstructured":"S.V. Vasaikar, P. Straub, J. Wang, B. Zhang, LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 46, D956\u2013D963 (2018). https:\/\/doi.org\/10.1093\/nar\/gkx1090","journal-title":"Nucleic Acids Res."},{"key":"1157_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn et al., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 462, 108\u2013112 (2009). https:\/\/doi.org\/10.1038\/nature08460","journal-title":"Nature"},{"key":"1157_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12864-019-6413-7","volume":"21","author":"D Chicco","year":"2020","unstructured":"D. Chicco, G. Jurman, The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genom. 21, 6 (2020). https:\/\/doi.org\/10.1186\/s12864-019-6413-7","journal-title":"BMC Genom."},{"key":"1157_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"K. Schulze, S. Imbeaud, E. Letouz\u00e9, L.B. Alexandrov, J. Calderaro, S. Rebouissou et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505\u2013511 (2015). https:\/\/doi.org\/10.1038\/ng.3252","journal-title":"Nat. Genet."},{"key":"1157_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2019.08.007","volume":"36","author":"L Ma","year":"2019","unstructured":"L. Ma, M.O. Hernandez, Y. Zhao, M. Mehta, B. Tran, M. Kelly et al., Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 36, 418\u2013430e6 (2019). https:\/\/doi.org\/10.1016\/j.ccell.2019.08.007","journal-title":"Cancer Cell."},{"key":"1157_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4252\/wjsc.v14.i7.539","volume":"14","author":"Q Chen","year":"2022","unstructured":"Q. Chen, S.-B. Yang, Y.-W. Zhang, S.-Y. Han, L. Jia, B. Li et al., miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma via a positive feedback loop involving FOXO3\/PI3K\/AKT\/c-Myc. World J. Stem Cells. 14, 539\u2013555 (2022). https:\/\/doi.org\/10.4252\/wjsc.v14.i7.539","journal-title":"World J. Stem Cells"},{"key":"1157_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/jpm11030219","volume":"11","author":"Y-L Yang","year":"2021","unstructured":"Y.-L. Yang, Y.-H. Chang, C.-J. Li, Y.-H. Huang, M.-C. Tsai, P.-Y. Chu et al., New insights into the role of miR-29a in hepatocellular carcinoma: implications in mechanisms and theragnostics. J. Pers. Med. 11, 219 (2021). https:\/\/doi.org\/10.3390\/jpm11030219","journal-title":"J. Pers. Med."},{"key":"1157_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/mol.115.101360","volume":"89","author":"J-P Gillet","year":"2016","unstructured":"J.-P. Gillet, J.B. Andersen, J.P. Madigan, S. Varma, R.K. Bagni, K. Powell et al., A gene expression signature associated with overall survival in patients with hepatocellular carcinoma suggests a new treatment strategy. Mol. Pharmacol. 89, 263\u2013272 (2016). https:\/\/doi.org\/10.1124\/mol.115.101360","journal-title":"Mol. Pharmacol."},{"key":"1157_CR28","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1038\/s41598-023-35796-z","volume":"13","author":"C Li","year":"2023","unstructured":"C. Li, X. Cui, Y. Li, D. Guo, S. He, Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in hepatocellular carcinoma. Sci. Rep. 13, 8681 (2023). https:\/\/doi.org\/10.1038\/s41598-023-35796-z","journal-title":"Sci. Rep."},{"key":"1157_CR29","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1158\/0008-5472.CAN-09-2823","volume":"70","author":"HG Woo","year":"2010","unstructured":"H.G. Woo, J.-H. Lee, J.-H. Yoon, C.Y. Kim, H.-S. Lee, J.J. Jang et al., Identification of a Cholangiocarcinoma-Like gene expression trait in hepatocellular carcinoma. Cancer Res. 70, 3034\u20133041 (2010). https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2823","journal-title":"Cancer Res."},{"key":"1157_CR30","doi-asserted-by":"publisher","unstructured":"D. Pan, Y. Du, R. Li, A. Shen, X. Liu, C. Li et al., miR-29b-3p increases radiosensitivity in stemness cancer cells via modulating oncogenes axis. Front. Cell. Dev. Biol. 9, (2021). https:\/\/doi.org\/10.3389\/fcell.2021.741074","DOI":"10.3389\/fcell.2021.741074"},{"key":"1157_CR31","doi-asserted-by":"publisher","first-page":"71309","DOI":"10.18632\/oncotarget.11885","volume":"7","author":"L Boix","year":"2016","unstructured":"L. Boix, J.M. L\u00f3pez-Oliva, A.C. Rhodes, J. Bruix, Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-\u03b2 pathway. Oncotarget. 7, 71309\u201371329 (2016). https:\/\/doi.org\/10.18632\/oncotarget.11885","journal-title":"Oncotarget"},{"key":"1157_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3892\/ol.2021.12887","volume":"22","author":"X-F Fu","year":"2021","unstructured":"X.-F. Fu, H.-C. Zhao, C.-L. Yang, C.-Z. Chen, K. Wang, F. Gao et al., MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. Oncol. Lett. 22, 626 (2021). https:\/\/doi.org\/10.3892\/ol.2021.12887","journal-title":"Oncol. Lett."},{"key":"1157_CR33","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/cas.13006","volume":"107","author":"J Azumi","year":"2016","unstructured":"J. Azumi, T. Tsubota, T. Sakabe, G. Shiota, miR-181a induces Sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Sci. 107, 1256\u20131262 (2016). https:\/\/doi.org\/10.1111\/cas.13006","journal-title":"Cancer Sci."},{"key":"1157_CR34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2023.08.056","volume":"679","author":"F Zhong","year":"2023","unstructured":"F. Zhong, Y. Wang, YY1-regulated LncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p\/CPEB1. Biochem. Biophys. Res. Commun. 679, 98\u2013109 (2023). https:\/\/doi.org\/10.1016\/j.bbrc.2023.08.056","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1157_CR35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018). https:\/\/doi.org\/10.1038\/nbt.4096","journal-title":"Nat. Biotechnol."},{"key":"1157_CR36","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.xgen.2025.100764","volume":"5","author":"M Di Giovannantonio","year":"2025","unstructured":"Di M. Giovannantonio, F. Hartley, B. Elshenawy, A. Barberis, D. Hudson, H.S. Shafique et al., Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures. Cell. Genom. 5, 100764 (2025). https:\/\/doi.org\/10.1016\/j.xgen.2025.100764","journal-title":"Cell. Genom"},{"key":"1157_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bbrc.2014.02.053","volume":"446","author":"H-J Noh","year":"2014","unstructured":"H.-J. Noh, K.-A. Kim, K.-C. Kim, p53 Down-regulates SETDB1 gene expression during Paclitaxel induced-cell death. Biochem. Biophys. Res. Commun. 446, 43\u201348 (2014). https:\/\/doi.org\/10.1016\/j.bbrc.2014.02.053","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1157_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40259-024-00702-0","volume":"39","author":"J Giron-Michel","year":"2025","unstructured":"J. Giron-Michel, M. Padelli, E. Oberlin, H. Guenou, J.-C. Duclos-Vall\u00e9e, State-of-the-Art liver cancer organoids: modeling cancer stem cell heterogeneity for personalized treatment. BioDrugs. 39, 237\u2013260 (2025). https:\/\/doi.org\/10.1007\/s40259-024-00702-0","journal-title":"BioDrugs"},{"key":"1157_CR39","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.7150\/thno.54648","volume":"11","author":"X Dai","year":"2021","unstructured":"X. Dai, Y. Guo, Y. Hu, X. Bao, X. Zhu, Q. Fu et al., Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics. 11, 3489\u20133501 (2021). https:\/\/doi.org\/10.7150\/thno.54648","journal-title":"Theranostics"},{"key":"1157_CR40","doi-asserted-by":"publisher","first-page":"1500263","DOI":"10.3389\/fcell.2024.1500263","volume":"12","author":"E Zhang","year":"2024","unstructured":"E. Zhang, P. He, The function of histone methyltransferase SETDB1 and its roles in liver cancer. Front. Cell. Dev. Biol. 12, 1500263 (2024). https:\/\/doi.org\/10.3389\/fcell.2024.1500263","journal-title":"Front. Cell. Dev. Biol."},{"key":"1157_CR41","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1002\/ijc.32432","volume":"145","author":"E Orouji","year":"2019","unstructured":"E. Orouji, A. Federico, L. Larrib\u00e8re, D. Novak, D.B. Lipka, Y. Assenov et al., Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int. J. Cancer. 145, 3462\u20133477 (2019). https:\/\/doi.org\/10.1002\/ijc.32432","journal-title":"Int. J. Cancer"},{"key":"1157_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/carcin\/bgz131","volume":"41","author":"L Yu","year":"2020","unstructured":"L. Yu, F. Ye, Y.-Y. Li, Y.-Z. Zhan, Y. Liu, H.-M. Yan et al., Histone methyltransferase SETDB1 promotes colorectal cancer proliferation through the STAT1-CCND1\/CDK6 axis. Carcinogenesis. 41, 678\u2013688 (2020). https:\/\/doi.org\/10.1093\/carcin\/bgz131","journal-title":"Carcinogenesis"},{"key":"1157_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1002\/hep.28304","volume":"63","author":"C-M Wong","year":"2016","unstructured":"C.-M. Wong, L. Wei, C.-T. Law, D.W.-H. Ho, F.H.-C. Tsang, S.L.-K. Au et al., Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology. 63, 474\u2013487 (2016). https:\/\/doi.org\/10.1002\/hep.28304","journal-title":"Hepatology"},{"key":"1157_CR44","doi-asserted-by":"publisher","first-page":"8651","DOI":"10.1038\/ncomms9651","volume":"6","author":"Q Fei","year":"2015","unstructured":"Q. Fei, K. Shang, J. Zhang, S. Chuai, D. Kong, T. Zhou et al., Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53. Nat. Commun. 6, 8651 (2015). https:\/\/doi.org\/10.1038\/ncomms9651","journal-title":"Nat. Commun."},{"key":"1157_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/0008-5472.CAN-20-2906","volume":"81","author":"D Strepkos","year":"2021","unstructured":"D. Strepkos, M. Markouli, A. Klonou, A.G. Papavassiliou, C. Piperi, Histone methyltransferase SETDB1: A common denominator of tumorigenesis with therapeutic potential. Cancer Res. 81, 525\u2013534 (2021). https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2906","journal-title":"Cancer Res."},{"key":"1157_CR46","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1093\/nar\/gkad796","volume":"51","author":"S Park","year":"2023","unstructured":"S. Park, J.H. Cho, J.-H. Kim, M. Park, S. Park, S.-Y. Kim et al., Hypoxia stabilizes SETDB1 to maintain genome stability. Nucleic Acids Res. 51, 11178\u201311196 (2023). https:\/\/doi.org\/10.1093\/nar\/gkad796","journal-title":"Nucleic Acids Res."},{"key":"1157_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/path.5126","volume":"246","author":"J-F Xiao","year":"2018","unstructured":"J.-F. Xiao, Q.-Y. Sun, L.-W. Ding, W. Chien, X.-Y. Liu, A. Mayakonda et al., The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis. J. Pathol. 246, 89\u2013102 (2018). https:\/\/doi.org\/10.1002\/path.5126","journal-title":"J. Pathol."},{"key":"1157_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.gep.2012.03.005","volume":"12","author":"S Cho","year":"2012","unstructured":"S. Cho, J.S. Park, S. Kwon, Y.-K. Kang, Dynamics of Setdb1 expression in early mouse development. Gene Expr Patterns. 12, 213\u2013218 (2012). https:\/\/doi.org\/10.1016\/j.gep.2012.03.005","journal-title":"Gene Expr Patterns"},{"key":"1157_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8935-2-12","volume":"2","author":"L-S Yeap","year":"2009","unstructured":"L.-S. Yeap, K. Hayashi, M.A. Surani, ERG-associated protein with SET domain (ESET)-Oct4 interaction regulates pluripotency and represses the trophectoderm lineage. Epigenetics Chromatin. 2, 12 (2009). https:\/\/doi.org\/10.1186\/1756-8935-2-12","journal-title":"Epigenetics Chromatin"},{"key":"1157_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/ng1760","volume":"38","author":"Y-H Loh","year":"2006","unstructured":"Y.-H. Loh, Q. Wu, J.-L. Chew, V.B. Vega, W. Zhang, X. Chen et al., The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat. Genet. 38, 431\u2013440 (2006). https:\/\/doi.org\/10.1038\/ng1760","journal-title":"Nat. Genet."},{"key":"1157_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.celrep.2019.12.010","volume":"30","author":"K Wu","year":"2020","unstructured":"K. Wu, H. Liu, Y. Wang, J. He, S. Xu, Y. Chen et al., SETDB1-Mediated cell fate transition between 2\u00a0C-Like and pluripotent States. Cell. Rep. 30, 25\u201336e6 (2020). https:\/\/doi.org\/10.1016\/j.celrep.2019.12.010","journal-title":"Cell. Rep."},{"key":"1157_CR52","doi-asserted-by":"publisher","first-page":"41115","DOI":"10.1074\/jbc.M111.248534","volume":"286","author":"S Cho","year":"2011","unstructured":"S. Cho, J.S. Park, Y.-K. Kang, Dual functions of histone-lysine N-methyltransferase Setdb1 protein at promyelocytic leukemia-nuclear body (PML-NB): maintaining PML-NB structure and regulating the expression of its associated genes. J. Biol. Chem. 286, 41115\u201341124 (2011). https:\/\/doi.org\/10.1074\/jbc.M111.248534","journal-title":"J. Biol. Chem."},{"key":"1157_CR53","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1002\/ctm2.335","volume":"11","author":"X Zhang","year":"2021","unstructured":"X. Zhang, B. Hu, Y.-F. Sun, X.-W. Huang, J.-W. Cheng, A. Huang et al., Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through Inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically. Clin. Transl Med. 11, e335 (2021). https:\/\/doi.org\/10.1002\/ctm2.335","journal-title":"Clin. Transl Med."},{"key":"1157_CR54","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1093\/nar\/gkad819","volume":"51","author":"C Fracassi","year":"2023","unstructured":"C. Fracassi, M. Ugge\u2019, M. Abdelhalim, E. Zapparoli, M. Simoni, D. Magliulo et al., PML modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer. Nucleic Acids Res. 51, 11024\u201311039 (2023). https:\/\/doi.org\/10.1093\/nar\/gkad819","journal-title":"Nucleic Acids Res."},{"key":"1157_CR55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"G.K. Griffin, J. Wu, A. Iracheta-Vellve, J.C. Patti, J. Hsu, T. Davis et al., Epigenetic Silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 595, 309\u2013314 (2021). https:\/\/doi.org\/10.1038\/s41586-021-03520-4","journal-title":"Nature"},{"key":"1157_CR56","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1016\/j.cell.2024.10.007","volume":"187","author":"Y Lyu","year":"2024","unstructured":"Y. Lyu, S.J. Kim, E.S. Humphrey, R. Nayak, Y. Guan, Q. Liang et al., Stem cell activity-coupled suppression of endogenous retrovirus governs adult tissue regeneration. Cell. 187, 7414\u20137432e26 (2024). https:\/\/doi.org\/10.1016\/j.cell.2024.10.007","journal-title":"Cell"},{"key":"1157_CR57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cells9010008","volume":"9","author":"X Jiao","year":"2019","unstructured":"X. Jiao, X. Qian, L. Wu, B. Li, Y. Wang, X. Kong et al., MicroRNA: the impact on cancer stemness and therapeutic resistance. Cells. 9, 8 (2019). https:\/\/doi.org\/10.3390\/cells9010008","journal-title":"Cells"},{"key":"1157_CR58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ymthe.2018.11.005","volume":"27","author":"Y Shao","year":"2019","unstructured":"Y. Shao, X. Song, W. Jiang, Y. Chen, Z. Ning, W. Gu et al., MicroRNA-621 acts as a tumor radiosensitizer by directly targeting SETDB1 in hepatocellular carcinoma. Mol. Ther. 27, 355\u2013364 (2019). https:\/\/doi.org\/10.1016\/j.ymthe.2018.11.005","journal-title":"Mol. Ther."},{"key":"1157_CR59","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-020-2561-6","volume":"11","author":"N Cao","year":"2020","unstructured":"N. Cao, Y. Yu, H. Zhu, M. Chen, P. Chen, M. Zhuo et al., SETDB1 promotes the progression of colorectal cancer via epigenetically Silencing p21 expression. Cell. Death Dis. 11, 351 (2020). https:\/\/doi.org\/10.1038\/s41419-020-2561-6","journal-title":"Cell. Death Dis."},{"key":"1157_CR60","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3892\/or.2018.6871","volume":"41","author":"W Yang","year":"2019","unstructured":"W. Yang, Y. Su, C. Hou, L. Chen, D. Zhou, K. Ren et al., SETDB1 induces epithelial\u2013mesenchymal transition in breast carcinoma by directly binding with snail promoter. Oncol. Rep. 41, 1284\u20131292 (2019). https:\/\/doi.org\/10.3892\/or.2018.6871","journal-title":"Oncol. Rep."},{"key":"1157_CR61","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1002\/stem.1795","volume":"32","author":"H Zhang","year":"2014","unstructured":"H. Zhang, K. Cai, J. Wang, X. Wang, K. Cheng, F. Shi et al., MiR-7, inhibited indirectly by LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 32, 2858\u20132868 (2014). https:\/\/doi.org\/10.1002\/stem.1795","journal-title":"Stem Cells"},{"key":"1157_CR62","doi-asserted-by":"publisher","first-page":"135","DOI":"10.15252\/embr.201744250","volume":"19","author":"D Du","year":"2018","unstructured":"D. Du, Y. Katsuno, D. Meyer, E.H. Budi, S. Chen, H. Koeppen et al., Smad3-mediated recruitment of the methyltransferase SETDB1\/ESET controls Snail1 expression and epithelial\u2013mesenchymal transition. EMBO Rep. 19, 135\u2013155 (2018). https:\/\/doi.org\/10.15252\/embr.201744250","journal-title":"EMBO Rep."},{"key":"1157_CR63","doi-asserted-by":"publisher","first-page":"109087","DOI":"10.1016\/j.abb.2021.109087","volume":"715","author":"T Liu","year":"2022","unstructured":"T. Liu, P. Xu, S. Ke, H. Dong, M. Zhan, Q. Hu et al., Histone methyltransferase SETDB1 inhibits TGF-\u03b2-induced epithelial-mesenchymal transition in pulmonary fibrosis by regulating SNAI1 expression and the ferroptosis signaling pathway. Arch. Biochem. Biophys. 715, 109087 (2022). https:\/\/doi.org\/10.1016\/j.abb.2021.109087","journal-title":"Arch. Biochem. Biophys."},{"key":"1157_CR64","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"S.A. Mani, W. Guo, M.-J. Liao, E. ENg, A. Ayyanan, A.Y. Zhou et al., The Epithelial-Mesenchymal transition generates cells with properties of stem cells. Cell. 133, 704\u2013715 (2008). https:\/\/doi.org\/10.1016\/j.cell.2008.03.027","journal-title":"Cell"},{"key":"1157_CR65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/1878-0261.12084","volume":"11","author":"MK Jolly","year":"2017","unstructured":"M.K. Jolly, S.C. Tripathi, J.A. Somarelli, S.M. Hanash, H. Levine, Epithelial\/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding? Mol. Oncol. 11, 739\u2013754 (2017). https:\/\/doi.org\/10.1002\/1878-0261.12084","journal-title":"Mol. Oncol."},{"key":"1157_CR66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000515289","volume":"211","author":"MK Jolly","year":"2022","unstructured":"M.K. Jolly, R.J. Murphy, S. Bhatia, H.J. Whitfield, A. Redfern, M.J. Davis et al., Measuring and modelling the Epithelial- mesenchymal hybrid state in cancer: clinical implications. Cells Tissues Organs. 211, 110\u2013133 (2022). https:\/\/doi.org\/10.1159\/000515289","journal-title":"Cells Tissues Organs."},{"key":"1157_CR67","doi-asserted-by":"publisher","unstructured":"C. Kr\u00f6ger, A. Afeyan, J. Mraz, E.N. Eaton, F. Reinhardt, Y.L. Khodor et al., Acquisition of a hybrid E\/M state is essential for tumorigenicity of basal breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 116, 7353\u20137362 (2019). https:\/\/doi.org\/10.1073\/pnas.1812876116","DOI":"10.1073\/pnas.1812876116"},{"key":"1157_CR68","doi-asserted-by":"publisher","first-page":"11109","DOI":"10.3390\/ijms252011109","volume":"25","author":"VM Perelmuter","year":"2024","unstructured":"V.M. Perelmuter, E.S. Grigoryeva, V.V. Alifanov, A.Y. Kalinchuk, E.S. Andryuhova, O.E. Savelieva et al., Characterization of EpCAM-Positive and EpCAM-Negative tumor cells in Early-Stage breast cancer. Int. J. Mol. Sci. 25, 11109 (2024). https:\/\/doi.org\/10.3390\/ijms252011109","journal-title":"Int. J. Mol. Sci."},{"key":"1157_CR69","doi-asserted-by":"publisher","first-page":"844013","DOI":"10.3389\/fcell.2022.844013","volume":"10","author":"G Zhang","year":"2022","unstructured":"G. Zhang, W. Fan, H. Wang, J. Wen, J. Tan, M. Xue et al., Non-Apoptotic programmed cell Death-Related gene signature correlates with stemness and immune status and predicts the responsiveness of transarterial chemoembolization in hepatocellular carcinoma. Front. Cell. Dev. Biol. 10, 844013 (2022). https:\/\/doi.org\/10.3389\/fcell.2022.844013","journal-title":"Front. Cell. Dev. Biol."},{"key":"1157_CR70","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12672-025-01909-5","volume":"16","author":"Q Zhu","year":"2025","unstructured":"Q. Zhu, S. Liao, T. Wei, S. Liu, C. Yang, J. Tang, Development of a novel prognostic signature based on cytotoxic T lymphocyte-evasion genes for hepatocellular carcinoma patient management. Discov Onc. 16, 144 (2025). https:\/\/doi.org\/10.1007\/s12672-025-01909-5","journal-title":"Discov Onc"},{"key":"1157_CR71","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2020.04.047","volume":"159","author":"S Ogawa","year":"2020","unstructured":"S. Ogawa, A. Fukuda, Y. Matsumoto, Y. Hanyu, M. Sono, Y. Fukunaga et al., SETDB1 inhibits p53-Mediated apoptosis and is required for formation of pancreatic ductal adenocarcinomas in mice. Gastroenterology. 159, 682\u2013696e13 (2020). https:\/\/doi.org\/10.1053\/j.gastro.2020.04.047","journal-title":"Gastroenterology"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01157-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01157-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:11:17Z","timestamp":1781626277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-025-01157-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1157"],"URL":"https:\/\/doi.org\/10.1007\/s13402-025-01157-3","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approvals and consent to participate"}},{"value":"All authors have given their approval for the manuscript to be submitted in its current form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}